Copyright Reports & Markets. All rights reserved.

Global Recurrent Glioblastoma Multiforme Treatment Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Recurrent Glioblastoma Multiforme Treatment Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate by Product
      • 1.4.2 AU-105
      • 1.4.3 Axitinib
      • 1.4.4 AXL-1717
      • 1.4.5 AZD-7451
      • 1.4.6 Others
    • 1.5 Market by End User
      • 1.5.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Recurrent Glioblastoma Multiforme Treatment Market Size
      • 2.1.1 Global Recurrent Glioblastoma Multiforme Treatment Revenue 2014-2025
      • 2.1.2 Global Recurrent Glioblastoma Multiforme Treatment Sales 2014-2025
    • 2.2 Recurrent Glioblastoma Multiforme Treatment Growth Rate by Regions
      • 2.2.1 Global Recurrent Glioblastoma Multiforme Treatment Sales by Regions
      • 2.2.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Recurrent Glioblastoma Multiforme Treatment Sales by Manufacturers
      • 3.1.1 Recurrent Glioblastoma Multiforme Treatment Sales by Manufacturers
      • 3.1.2 Recurrent Glioblastoma Multiforme Treatment Sales Market Share by Manufacturers
      • 3.1.3 Global Recurrent Glioblastoma Multiforme Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Recurrent Glioblastoma Multiforme Treatment Revenue by Manufacturers
      • 3.2.1 Recurrent Glioblastoma Multiforme Treatment Revenue by Manufacturers (2014-2019)
      • 3.2.2 Recurrent Glioblastoma Multiforme Treatment Revenue Share by Manufacturers (2014-2019)
    • 3.3 Recurrent Glioblastoma Multiforme Treatment Price by Manufacturers
    • 3.4 Recurrent Glioblastoma Multiforme Treatment Manufacturing Base Distribution, Product Types
      • 3.4.1 Recurrent Glioblastoma Multiforme Treatment Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Recurrent Glioblastoma Multiforme Treatment Product Type
      • 3.4.3 Date of International Manufacturers Enter into Recurrent Glioblastoma Multiforme Treatment Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Recurrent Glioblastoma Multiforme Treatment Sales by Product
    • 4.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue by Product
    • 4.3 Recurrent Glioblastoma Multiforme Treatment Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Recurrent Glioblastoma Multiforme Treatment Breakdown Data by End User

    6 North America

    • 6.1 North America Recurrent Glioblastoma Multiforme Treatment by Countries
      • 6.1.1 North America Recurrent Glioblastoma Multiforme Treatment Sales by Countries
      • 6.1.2 North America Recurrent Glioblastoma Multiforme Treatment Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Recurrent Glioblastoma Multiforme Treatment by Product
    • 6.3 North America Recurrent Glioblastoma Multiforme Treatment by End User

    7 Europe

    • 7.1 Europe Recurrent Glioblastoma Multiforme Treatment by Countries
      • 7.1.1 Europe Recurrent Glioblastoma Multiforme Treatment Sales by Countries
      • 7.1.2 Europe Recurrent Glioblastoma Multiforme Treatment Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Recurrent Glioblastoma Multiforme Treatment by Product
    • 7.3 Europe Recurrent Glioblastoma Multiforme Treatment by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Recurrent Glioblastoma Multiforme Treatment by Countries
      • 8.1.1 Asia Pacific Recurrent Glioblastoma Multiforme Treatment Sales by Countries
      • 8.1.2 Asia Pacific Recurrent Glioblastoma Multiforme Treatment Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Recurrent Glioblastoma Multiforme Treatment by Product
    • 8.3 Asia Pacific Recurrent Glioblastoma Multiforme Treatment by End User

    9 Central & South America

    • 9.1 Central & South America Recurrent Glioblastoma Multiforme Treatment by Countries
      • 9.1.1 Central & South America Recurrent Glioblastoma Multiforme Treatment Sales by Countries
      • 9.1.2 Central & South America Recurrent Glioblastoma Multiforme Treatment Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Recurrent Glioblastoma Multiforme Treatment by Product
    • 9.3 Central & South America Recurrent Glioblastoma Multiforme Treatment by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Recurrent Glioblastoma Multiforme Treatment by Countries
      • 10.1.1 Middle East and Africa Recurrent Glioblastoma Multiforme Treatment Sales by Countries
      • 10.1.2 Middle East and Africa Recurrent Glioblastoma Multiforme Treatment Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Recurrent Glioblastoma Multiforme Treatment by Product
    • 10.3 Middle East and Africa Recurrent Glioblastoma Multiforme Treatment by End User

    11 Company Profiles

    • 11.1 Boehringer Ingelheim GmbH
      • 11.1.1 Boehringer Ingelheim GmbH Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Products Offered
      • 11.1.5 Boehringer Ingelheim GmbH Recent Development
    • 11.2 Boston Biomedical, Inc.
      • 11.2.1 Boston Biomedical, Inc. Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Products Offered
      • 11.2.5 Boston Biomedical, Inc. Recent Development
    • 11.3 Bristol-Myers Squibb Company
      • 11.3.1 Bristol-Myers Squibb Company Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Products Offered
      • 11.3.5 Bristol-Myers Squibb Company Recent Development
    • 11.4 Cantex Pharmaceuticals, Inc.
      • 11.4.1 Cantex Pharmaceuticals, Inc. Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Products Offered
      • 11.4.5 Cantex Pharmaceuticals, Inc. Recent Development
    • 11.5 Cavion LLC
      • 11.5.1 Cavion LLC Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Cavion LLC Recurrent Glioblastoma Multiforme Treatment Products Offered
      • 11.5.5 Cavion LLC Recent Development
    • 11.6 Celldex Therapeutics, Inc.
      • 11.6.1 Celldex Therapeutics, Inc. Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Products Offered
      • 11.6.5 Celldex Therapeutics, Inc. Recent Development
    • 11.7 Coherus BioSciences, Inc.
      • 11.7.1 Coherus BioSciences, Inc. Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Products Offered
      • 11.7.5 Coherus BioSciences, Inc. Recent Development
    • 11.8 Cortice Biosciences, Inc.
      • 11.8.1 Cortice Biosciences, Inc. Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Products Offered
      • 11.8.5 Cortice Biosciences, Inc. Recent Development
    • 11.9 Eisai
      • 11.9.1 Eisai Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Eisai Recurrent Glioblastoma Multiforme Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Eisai Recurrent Glioblastoma Multiforme Treatment Products Offered
      • 11.9.5 Eisai Recent Development
    • 11.10 Eli Lilly and Company
      • 11.10.1 Eli Lilly and Company Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Products Offered
      • 11.10.5 Eli Lilly and Company Recent Development
    • 11.11 EnGeneIC Ltd
    • 11.12 ERC Belgium SA
    • 11.13 GenSpera, Inc.
    • 11.14 Genzyme Corporation
    • 11.15 GW Pharmaceuticals Plc
    • 11.16 ImmunoCellular Therapeutics, Ltd.

    12 Future Forecast

    • 12.1 Recurrent Glioblastoma Multiforme Treatment Market Forecast by Regions
      • 12.1.1 Global Recurrent Glioblastoma Multiforme Treatment Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue Forecast by Regions 2019-2025
    • 12.2 Recurrent Glioblastoma Multiforme Treatment Market Forecast by Product
      • 12.2.1 Global Recurrent Glioblastoma Multiforme Treatment Sales Forecast by Product 2019-2025
      • 12.2.2 Global Recurrent Glioblastoma Multiforme Treatment Revenue Forecast by Product 2019-2025
    • 12.3 Recurrent Glioblastoma Multiforme Treatment Market Forecast by End User
    • 12.4 North America Recurrent Glioblastoma Multiforme Treatment Forecast
    • 12.5 Europe Recurrent Glioblastoma Multiforme Treatment Forecast
    • 12.6 Asia Pacific Recurrent Glioblastoma Multiforme Treatment Forecast
    • 12.7 Central & South America Recurrent Glioblastoma Multiforme Treatment Forecast
    • 12.8 Middle East and Africa Recurrent Glioblastoma Multiforme Treatment Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Recurrent Glioblastoma Multiforme Treatment Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Recurrent Glioblastoma Multiforme Treatment market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Recurrent Glioblastoma Multiforme Treatment market based on company, product type, end user and key regions.

      This report studies the global market size of Recurrent Glioblastoma Multiforme Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Recurrent Glioblastoma Multiforme Treatment in these regions.
      This research report categorizes the global Recurrent Glioblastoma Multiforme Treatment market by top players/brands, region, type and end user. This report also studies the global Recurrent Glioblastoma Multiforme Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Boehringer Ingelheim GmbH
      Boston Biomedical, Inc.
      Bristol-Myers Squibb Company
      Cantex Pharmaceuticals, Inc.
      Cavion LLC
      Celldex Therapeutics, Inc.
      Coherus BioSciences, Inc.
      Cortice Biosciences, Inc.
      Eisai
      Eli Lilly and Company
      EnGeneIC Ltd
      ERC Belgium SA
      GenSpera, Inc.
      Genzyme Corporation
      GW Pharmaceuticals Plc
      ImmunoCellular Therapeutics, Ltd.

      Market size by Product
      AU-105
      Axitinib
      AXL-1717
      AZD-7451
      Others
      Market size by End User
      Hospital
      Clinic
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Recurrent Glioblastoma Multiforme Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Recurrent Glioblastoma Multiforme Treatment market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Recurrent Glioblastoma Multiforme Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Recurrent Glioblastoma Multiforme Treatment submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Recurrent Glioblastoma Multiforme Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Recurrent Glioblastoma Multiforme Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now